ReviewArchives of dermatological research2025
Anti-IL 17 biologics and pyoderma gangrenosum - therapeutic or causal?
Review in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Cloud-Based and Locally Deployed Language Models in Nursing and Health Care: An AI Act-Aligned Framework.JMIR medical informatics · 2026Article
- NLRP3 inflammasome activation is associated with type 1 inflammation and neutrophil activation in pyoderma gangrenosum across human and murine models.JID innovations : skin science from molecules to population health · 2026Article
- Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics.Clinical rheumatology · 2026Article
- Pyoderma Gangrenosum Masquerading as Chronic Infective Ulcers: Two Case Reports Across Age Extremes.Clinical case reports · 2026Article
- Bimekizumab for recalcitrant pyoderma gangrenosum.JAAD case reports · 2026Article
- Disrupted Redox Regulation and Inflammatory Response in Pyoderma Gangrenosum.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by pustules that rapidly progress into ulcers that commonly affect the lower limbs. Recently, successful treatment of PG has been reported with anti-IL 17 treatments. However, there have also been several reports of "paradoxical" induction of new PG lesions after use of IL-17 inhibitors. In this narrative review, we present the currently published English literature on cases in which PG has been successfully treated with IL-17 inhibitors and cases of possible newly induced PG after the use of IL-17 inhibitors. After use of the Naranjo Adverse Drug Reaction Probability Scale, it is difficult to conclude an adverse reaction of PG from anti-IL 17 biological agents. Our review also concludes that IL-23 and IL-36 inhibitors can be considered an alternative treatment for PG.
Indexed as
Identifiers
39804471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.